Paul Rugman
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 15, 2022
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Journal: Cancer discovery
Published: February 15, 2020
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 13, 2019
Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma.
Journal: Drug design, development and therapy
Published: May 17, 2018
Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.
Journal: The Journal of allergy and clinical immunology
Published: October 09, 2017
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Journal: Cancer chemotherapy and pharmacology
Published: October 04, 2017
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 03, 2017
Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease.
Journal: The Journal of allergy and clinical immunology
Published: February 02, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026